SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer

SARIFA as a new histopathological biomarker is associated with adverse clinicopathological characteristics, tumor-promoting fatty-acid metabolism, and might predict a metastatic pattern in pT3a prostate cancer

Abstract Background Recently, we introduced Stroma-AReactive-Invasion-Front-Areas (SARIFA) as a novel hematoxylin–eosin (H&E)-based histopathologic prognostic biomarker for various gastrointestinal cancers, closely related to lipid metabolism. To date, no studies on SARIFA, which is defined as d...

Full description

Bibliographic Details
Main Authors: Johanna S. Enke, Matthias Groß, Bianca Grosser, Eva Sipos, Julie Steinestel, Phillip Löhr, Johanna Waidhauser, Constantin Lapa, Bruno Märkl, Nic G. Reitsam
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Cancer
Subjects:
Prostate cancer
Lipid metabolism
Biomarker study
Prognostic biomarker
pT3a prostate cancer
Online Access:https://doi.org/10.1186/s12885-023-11771-9

Internet

https://doi.org/10.1186/s12885-023-11771-9

Similar Items